BALTIMORE, May 10, 2011 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of Nuvilex, Inc. (Pink Sheets:NVLX), an innovative natural products and biotechnology company.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines the reasoning behind the coverage initiation.
"We believe that Nuvilex is poised to emerge as a leader in four key market segments of the $150 billion natural products space: Nutraceuticals, Cosmetics, "Green" Cleansers, and Lawn/Crop Protection. Plus, the new Nuvilex leadership has engaged in pre-clinical development of natural product-based biotechnology products such as the anti-cancer agent Alterna™ offers huge potential."
To view a summary of the report or download the report in its entirety, please visit .
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap stock market research reports and weekly newsletters. For more information, visit .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research, disclosures, or for more information, visit .
About Nuvilex, Inc.: Nuvilex, Inc. (Pink Sheets:NVLX) is a Green Company believing in "Good for You, Good for the Environment," expanding its natural product lines and entering into biotechnology (www.nuvilex.com). Current products include Cinnergen™ for healthy glucose maintenance; Cinnechol™ to maintain healthy lipids and cardiovasculature; Cinnsational™ to decrease detrimental alcohol effects; Talsyn™ for keloids, erythema, and scar management; NumaDerm™ cosmetic products; Citroxin™ and Oraphyte™ antimicrobial and antinematodal agents; Reme-Flu™, Legacy Biotechnologies' flu combating regimen; and Virgin® and Infinitink®, heavy-metal-free tattoo inks.
For additional information, please visit the Company's website: .
CONTACT: Goldman Small Cap Research Rob Goldman, Analyst 410-609-7100 email@example.com